Navigation Links
The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Date:8/14/2013

BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although currently not FDA-approved for treatment of ovarian cancer, is prescribed by approximately 70 percent of surveyed oncologists in first-line advanced ovarian cancer. Avastin is most frequently prescribed in first-line advanced ovarian cancer as an add-on agent to doublet platinum-based chemotherapy followed by continued administration of Avastin as a maintenance monotherapy. Approximately half of the surveyed oncologists who prescribe Avastin in first-line advanced ovarian cancer indicate that they encounter reimbursement barriers (such as prior authorization) when prescribing Avastin in this setting.

The U.S. Physician and Payer Forum report entitled Ovarian and Endometrial Cancer: How Will U.S. Prescriber and Payer Attitudes Toward Emerging Antiangiogenics and Other Targeted Anticancer Agents Shape the Treatment Landscape? finds that current treatment of ovarian and endometrial cancers relies heavily on generically available chemotherapies and that carboplatin/paclitaxel is very frequently prescribed in early-stage ovarian cancer, first-line advanced ovarian cancer and in early-stage and advanced endometrial cancer. However, the use of Avastin for treatment of ovarian cancer in all disease settings is common amongst surveyed oncologists and more than 65 percent of surveyed oncologists think that treatment rates with Avastin will increase in the next five years - primarily because they believe Avastin will gain regulatory approval for ovarian cancer. Avastin is rarely used by surveyed oncologists for treatment of endometrial cancer; however, surveyed oncologists believe that angiogenesis inhibitors can play a role in its treatment with 70 percent of surveyed oncologists responding that targeting the vascular endothelial growth factor (VEGF) pathway will likely be a promising treatment approach in this disease.

The report also finds that demonstrating a survival advantage over currently available therapies is of paramount importance to most surveyed managed care organizations' (MCOs) pharmacy directors (PDs) for formulary inclusion and favorable tier status for ovarian cancer therapies. Surveyed MCO PDs indicate that the cost of treatment has a smaller impact on these decisions.

"The high use of off-label Avastin in ovarian cancer means that novel therapies for ovarian cancer, such as Amgen/Takeda Pharmaceutical's trebananib, Merck/Endocyte's vintafolide and GlaxoSmithKline's Votrient (pazopanib), will not only face strong competition from generically available chemotherapies, but also from premium-priced Avastin," said Decision Resources Senior Business Insights Analyst Karen Pomeranz, Ph.D. "Strong efficacy data and competitive pricing of emerging therapies compared with Avastin will encourage a high proportion of surveyed MCO PDs to offer reimbursement to novel ovarian cancer therapies and physicians to incorporate these agents into the treatment algorithm."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Completes Sale of Majority of Discovery Labware Unit
2. Allscripts adopts majority voting policy for directors
3. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. Majority of Springfield Voters Oppose Prescription Only PSE Requirements
6. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
7. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Open Access Journal ... Elsevier , a world-leading provider of ... announced the launch of Clinical Neurophysiology ... focuses on clinical practice issues in clinical neurophysiology. The ... normal values and didactic reviews. It is an official ...
(Date:5/23/2016)... PUNE, India , May 23, 2016 ... is spread across 163 pages, profiles 12 companies and ... 280 tables and figures on the industry and its ... study that is comprehensive in nature, details the current ... of the industry including definitions, classifications, applications and industry ...
(Date:5/23/2016)... 23, 2016 Clarifying Vision - ... Monitoring, and Vision Care What can be ... going to grow at the fastest rates? This ... assessing data, trends, opportunities and prospects. ... Discover the most lucrative areas in the industry and ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more ... more gluten-free products are available and easily accessible. Whether someone chooses to cut gluten ... to a certain diet, King Kullen Grocery stocks their shelves with many different gluten-free ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is ... leader in the development of technological innovations that lead to broad-based healthcare solutions. ...
(Date:5/24/2016)... Lake Orion, Michigan (PRWEB) , ... May 24, 2016 , ... ... Aroma Yoga. , The Yoga practice enhanced with Young Living Essential Oils, taught ... 6:30pm - 8pm at the Lake Orion location. Yoga Flow is 6:30pm - 7:15pm ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, on May ... transplant in the United States . The 64-year-old patient who received the transplant had ... could restore not only a natural appearance, but also urinary and sexual function for ...
(Date:5/24/2016)... ... May 24, 2016 , ... Controlling and maintaining the home’s water heater ... the Aquanta Water Heater Controller , a first-of-its-kind system that enables remote and ... As the Nest thermostat does for HVAC systems, Aquanta gives users a much more ...
Breaking Medicine News(10 mins):